Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term H. pylori Reinfection: Bismuth Quadruple vs Moxifloxacin Triple Therapy
NCT01792700Phase 4Completed
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Jan 2003
- Primary completion
- Dec 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of moxifloxacin in Helicobacter pylori infection (2 arms), sponsored by Seoul National University Bundang Hospital. Primary endpoint: Helicobacter pylori reinfection rate up to 90 months. Started Jan 2003; status: completed.
02
Drugs
moxifloxacin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT01792700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01792700.